secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001628280-25-015901
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion appoints Robert E. Hoffman to board; two directors resign effective June 1
--------------------------------------------------------------------------------

- Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D.Phil. resign from board effective June 1, 2025; no disagreement cited.
- Robert E. Hoffman elected independent director effective April 1, 2025; will chair Audit Committee from May 29, 2025.
- Hoffman brings CFO and CEO experience from Heron, AnaptysBio, Arena, Kintara, and multiple biotech boards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025015901/0001628280-25-015901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025015901/espr-20250401.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-015901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer